T1	Participants 49 57	children
T2	Participants 20 45	treatment of irritability
T3	Participants 207 232	treatment of irritability
T4	Participants 323 395	tantrums, aggression, self-injurious behavior, or a combination of these
T5	Participants 569 685	Patients were randomly assigned (1:1) to flexibly dosed aripiprazole (target dosage: 5, 10, or 15 mg/day) or placebo
T6	Participants 838 880	Safety and tolerability were also assessed
T7	Participants 994 1153	improvement in Aberrant Behavior Checklist irritability subscale score was significantly greater with aripiprazole than with placebo from week 1 through week 8
T8	Participants 1433 1495	events (AEs) were 10.6% for aripiprazole and 5.9% for placebo.
T9	Participants 1496 1584	Extrapyramidal symptom-related AE rates were 14.9% for aripiprazole and 8.0% for placebo
T10	Participants 1586 1614	No serious AEs were reported
T11	Participants 1616 1691	Mean weight gain was 2.0 kg on aripiprazole and 0.8 kg on placebo at week 8
T12	Participants 1705 1856	Aripiprazole was efficacious in children and adolescents with irritability associated with autistic disorder and was generally safe and well tolerated.
